Epileptic Syndromes: Clinical Trials

56 trials for Epileptic Syndromes, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 15 terminated, 11 recruiting, 7 active not recruiting. 56 Phase 2, 15 Phase 1, 11 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 256Completed 15, Terminated 15, Recruiting 11, Active not recruiting 7, Unknown 6, Not yet recruiting 1, Withdrawn 1
Phase 115Active not recruiting 5, Recruiting 5, Completed 3, Not yet recruiting 1, Terminated 1
Phase 311Unknown 5, Terminated 3, Completed 1, Recruiting 1, Withdrawn 1

Follow Epileptic Syndromes: new trials by email Literature Review of Epileptic Syndromes trials Research Report on Epileptic Syndromes

Trials (filtered) newest first · largest first

All 56 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related Disorders
Glycerol Phenylbutyrate - SLC6A1
Phase 2RecruitingScripps Translational Science Institute202026-10-012026-09-29
A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy
JZP926 capsule, Placebo - Juvenile Myoclonic Epilepsy
Phase 2 / Phase 3RecruitingJazz Pharmaceuticals2602026-09-182026-11-12
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
ION337 - Dravet Syndrome
Phase 1 / Phase 2RecruitingIonis Pharmaceuticals, Inc.322026-05-212026-11-02
Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation
nL-ATN1-001 - Dentatorubral-Pallidoluysian Atrophy
Phase 1 / Phase 2Active not recruitingn-Lorem Foundation12025-11-062026-04-07
A Study to Prevent Infantile Spasms Relapse
Prednisolone, Famotidine, Placebo - Infantile Spasms, Infantile Epileptic Spasms Syndrome
Phase 2RecruitingUniversity of California, Los Angeles402025-05-052025-05-08
Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy
Ferumoxytol - Epilepsy, Temporal Lobe
Phase 2RecruitingUniversity of Alberta502025-05-012026-05-08
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
NPT 2042, Placebo - Epilepsy, Generalized, Epilepsy, Absence
Phase 2CompletedNeuroPro Therapeutics, Inc.142025-03-112026-09-28
CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome
CBD: GT4 Transdermal Delivery System - Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS)
Phase 1 / Phase 2Not yet recruitingAlexander Rotenberg252025-01-012024-12-18
BMB-101 in Absence Epilepsy and DEE
BMB-101 - Absence Epilepsy, Jeavons Syndrome
Phase 2RecruitingBright Minds Biosciences Pty Ltd202024-12-052025-08-12
A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease
ION283 - Lafora Disease
Phase 1 / Phase 2RecruitingBerge Minassian102024-12-032025-12-18
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
NRTX-1001 - Epilepsy, Temporal Lobe
Phase 1 / Phase 2RecruitingNeurona Therapeutics102024-11-142026-01-07
Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation
nL-ATN1-002 - Dentatorubral-Pallidoluysian Atrophy
Phase 1 / Phase 2Active not recruitingn-Lorem Foundation12024-10-242026-07-13
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
BHV-7000, Placebo - Generalized Epilepsy
Phase 2 / Phase 3TerminatedBiohaven Therapeutics Ltd.272024-06-202026-03-24
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
AAV9-hSyn1-miGRIK2 - Mesial Temporal Lobe Epilepsy
Phase 1 / Phase 2RecruitingUniQure Biopharma B.V.122024-06-122026-08-24
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
ETX101 - Dravet Syndrome
Phase 1 / Phase 2RecruitingEncoded Therapeutics1132024-05-142026-10-23
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
ETX101 - Dravet Syndrome
Phase 1 / Phase 2Active not recruitingEncoded Therapeutics52024-05-092026-06-08
Cortical Excitability in West Syndrome Using Transcranial Magnetic Stimulation
ACTH/Oral Steroids - West Syndrome
Phase 2 / Phase 3UnknownAll India Institute of Medical Sciences402024-03-012024-03-04
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
ETX101 - Dravet Syndrome
Phase 1 / Phase 2Active not recruitingEncoded Therapeutics42024-02-282025-11-14
Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation
nL-ATN1-002 - Dentatorubral-Pallidoluysian Atrophy
Phase 1 / Phase 2Active not recruitingn-Lorem Foundation12024-02-212026-04-09
Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).
Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN) - Mitochondrial Diseases, Mitochondrial Myopathies
Phase 1 / Phase 2CompletedChildren's Hospital of Philadelphia162023-09-222024-11-29

Showing 20 of 56. Sign in to see all of them.

Narrower conditions

Epilepsies, Myoclonic (18)  ·  Spasms, Infantile (16)  ·  Epilepsy (14)  ·  Lennox Gastaut Syndrome (9)  ·  Seizures (8)  ·  Epilepsy, Absence (7)  ·  Epilepsy, Temporal Lobe (4)  ·  CDKL5 deficiency disorder (3)  ·  Leigh Disease (3)  ·  MELAS Syndrome (3)  ·  MERRF Syndrome (3)  ·  Mitochondrial Diseases (3)  ·  Mitochondrial Encephalomyopathies (3)  ·  Myoclonic Epilepsies, Progressive (3)  ·  Myoclonic Epilepsy, Juvenile (3)

Broader conditions

Brain Diseases (55)  ·  Central Nervous System Diseases (55)  ·  Nervous System Diseases (55)  ·  Epilepsy, Generalized (46)  ·  Epilepsy (42)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (17)  ·  Genetic Diseases, Inborn (16)  ·  Pathological Conditions, Signs and Symptoms (14)  ·  Signs and Symptoms (13)  ·  Neurologic Manifestations (12)  ·  Epilepsies, Myoclonic (11)  ·  Heredodegenerative Disorders, Nervous System (7)  ·  Neurodegenerative Diseases (7)  ·  Pathologic Processes (6)

Interventions

Cannabidiol (5)  ·  Adrenocorticotropic Hormone (2)  ·  Cysteamine (2)  ·  Diet, Ketogenic (2)  ·  Fenfluramine (2)  ·  Topiramate (2)  ·  ganaxolone (2)  ·  Acetazolamide (1)  ·  Buspirone (1)  ·  Carbamazepine (1)  ·  Diazepam (1)  ·  Diet Therapy (1)  ·  Famotidine (1)  ·  Ferrosoferric Oxide (1)  ·  Flunarizine (1)

Sponsors

All India Institute of Medical Sciences (3)  ·  Encoded Therapeutics (3)  ·  Lady Hardinge Medical College (3)  ·  n-Lorem Foundation (3)  ·  Amgen (2)  ·  Gillette Children's Specialty Healthcare (2)  ·  Jazz Pharmaceuticals (2)  ·  Longboard Pharmaceuticals (2)  ·  Marinus Pharmaceuticals (2)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (2)  ·  Radius Pharmaceuticals, Inc. (2)  ·  Stoke Therapeutics, Inc (2)  ·  Takeda (2)  ·  Alexander Rotenberg (1)  ·  Berge Minassian (1)

Countries

United States (38)  ·  Australia (8)  ·  India (7)  ·  Canada (6)  ·  United Kingdom (5)  ·  Poland (4)  ·  Spain (4)  ·  France (3)  ·  Italy (3)  ·  Portugal (3)  ·  Belgium (2)  ·  China (2)  ·  Finland (2)  ·  Germany (2)  ·  Israel (2)

Top investigators

Ahmed Elkashef, MD (2)  ·  Ann Dandurand, MD (2)  ·  Beverly S Wical, MD (2)  ·  Dennis J Dlugos, MD (2)  ·  Salvador Rico, M.D., Ph.D (2)  ·  Suvasini Sharma, MD, DM (2)  ·  William H Theodore, M.D. (2)  ·  Alexander Rotenberg, MD, PhD (1)  ·  Berge Minassian, MD (1)  ·  Daniel Shrey, MD (1)  ·  Dipti Kapoor, MD (1)  ·  Donald Gross, MD (1)  ·  Eduardo Dunayevich, MD (1)

Results publications

PMID 41780062, PMID 21920781, PMID 30146701, PMID 33575989, PMID 33834913, PMID 35841234, PMID 40840039, PMID 42663529

NIH funding

2018 (2), 2014 (1), 2016 (1), 2023 (1), K12TR004410 (1), U54NS078059 (1), UH3NS109557 (1)